Effect of COVID-19 vaccination and booster on maternal-fetal outcomes: a retrospective cohort study.

Autor:	Piekos SN; Institute for Systems Biology, Seattle, WA, USA., Hwang YM; Institute for Systems Biology, Seattle, WA, USA., Roper RT; Institute for Systems Biology, Seattle, WA, USA., Sorensen T; Swedish Health Services, Swedish Medical Center, Seattle, WA, USA., Price ND; Institute for Systems Biology, Seattle, WA, USA; Thorne HealthTech, New York, NY, USA., Hood L; Institute for Systems Biology, Seattle, WA, USA., Hadlock JJ; Institute for Systems Biology, Seattle, WA, USA. Electronic address: jhadlock@isbscience.org.
Jazyk:	angličtina
Zdroj:	The Lancet. Digital health [Lancet Digit Health] 2023 Sep; Vol. 5 (9), pp. e594-e606. Date of Electronic Publication: 2023 Aug 01.
DOI:	10.1016/S2589-7500(23)00093-6
Abstrakt:	Background: COVID-19 in pregnant people increases the risk for poor maternal-fetal outcomes. However, COVID-19 vaccination hesitancy remains due to concerns over the vaccine's potential effects on maternal-fetal outcomes. Here we examine the impact of COVID-19 vaccination and boosters on maternal SARS-CoV-2 infections and birth outcomes. Methods: This was a retrospective multicentre cohort study on the impact of COVID-19 vaccination on maternal-fetal outcomes for people who delivered (n=106 428) at Providence St Joseph Health across seven western US states from Jan 26, 2021 to Oct 26, 2022. Cohorts were defined by vaccination status at delivery: vaccinated (n=35 926; two or more doses of mRNA-1273 Moderna or BNT162b2 Pfizer-BioNTech), unvaccinated (n=55 878), unvaccinated propensity score matched (n=16 771), boosted (n=10 927; three or more doses), vaccinated unboosted (n=13 243; two doses only), and vaccinated unboosted with propensity score matching (n=4414). We built supervised machine learning classification models, which we used to determine which people were more likely to be vaccinated or boosted at delivery. The primary outcome was maternal SARS-CoV-2 infection. COVID-19 vaccination status at delivery, COVID-19-related health care, preterm birth, stillbirth, and very low birthweight were evaluated as secondary outcomes. Findings: Vaccinated people were more likely to conceive later in the pandemic, have commercial insurance, be older, live in areas with lower household composition vulnerability, and have a higher BMI than unvaccinated people. Boosted people were more likely to have more days since receiving the second COVID-19 vaccine dose, conceive earlier in the pandemic, have commercial insurance, be older, and live in areas with lower household composition vulnerability than vaccinated unboosted people. Vaccinated pregnant people had lower rates of COVID-19 during pregnancy (4·0%) compared with unvaccinated matched people (5·3%; p<0·0001). COVID-19 rates were even lower in boosted people (3·2%) compared with vaccinated unboosted matched people (5·6%; p<0·0001). Vaccinated people were also less likely to have a preterm birth (7·9%; p<0·0001), stillbirth (0·3%; p<0·0002), or very low birthweight neonate (1·0%; p<0·0001) compared with unvaccinated matched people (preterm birth 9·4%; stillbirth 0·6%; very low birthweight 1·5%). Boosted people were less likely to have a stillbirth (0·3%; p<0·025) and have no differences in rates of preterm birth (7·6%; p=0·090) or very low birthweight neonates (0·8%; p=0·092) compared with vaccinated unboosted matched people (stillbirth 0·5%; preterm birth 8·4%; very low birthweight 1·1%). Interpretation: COVID-19 vaccination protects against adverse maternal-fetal outcomes, with booster doses conferring additional protection. Pregnant people should be high priority for vaccination and stay up to date with their COVID-19 vaccination schedule. Funding: National Institute for Child Health & Human Development and the William O and K Carole Ellison Foundation. Competing Interests: Declaration of interests LH and NDP are scientific advisors for Sera Prognostics, a pregnancy diagnostics company, and NDP holds stock options. The company is not associated with this study or any of the findings. NDP is the Chief Science Officer of Thorne HealthTech. JJH has received grant funding from Pfizer and Novartis and contract funding from Janssen, Gilead, and Bristol Myers Squibb for research unrelated to this work. All other authors declare no competing interests. (Copyright © 2023 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu